Our systematic review with meta-analysis on the risk of intracranial meningiomas associated with progestin drugs, conducted in partnership with GHU PARIS, neurosurgery department of Professor Johan Pallud.

By analyzing 78 international studies, we show:
– a major increased risk with cyproterone acetate (estimated at 12.4)
– an increased risk with medroxyprogesterone acetate
– signals for other macroprogestins (chlormadinone acetate, nomegestrol acetate, promegestone, medrogestone, desogestrel)
– An increased risk of malignant meningiomas for certain molecules
– A predominance of locations at the base of the skull
– A possible but not systematic regression of the size of the meningioma after stopping treatment.

The level of evidence varies according to the molecules, but these data reinforce the need to clearly inform patients, to limit prescriptions (strictly necessary indication, minimum dose, minimum duration) and to ensure appropriate monitoring in case of prolonged exposure .

Read the study here: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00038-6/fulltext

Thanks to Benoit Hudelist and the entire neurosurgery team at GHU Paris Psychiatry and Neuroscience – Sainte-Anne for this collaborative work.